Ellsworth Advisors LLC Makes New $734,000 Investment in Electromed, Inc. (NYSE:ELMD)

Ellsworth Advisors LLC acquired a new stake in shares of Electromed, Inc. (NYSE:ELMD) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 24,834 shares of the company’s stock, valued at approximately $734,000. Ellsworth Advisors LLC owned approximately 0.29% of Electromed at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC purchased a new position in Electromed during the third quarter valued at $215,000. Wilmington Savings Fund Society FSB bought a new position in shares of Electromed during the 3rd quarter valued at about $226,000. Legacy Wealth Asset Management LLC purchased a new position in shares of Electromed during the fourth quarter valued at about $253,000. Marshall Wace LLP purchased a new position in shares of Electromed during the second quarter valued at about $256,000. Finally, Walleye Capital LLC bought a new stake in shares of Electromed in the third quarter worth about $274,000. Institutional investors own 40.82% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 9th.

Electromed Stock Performance

ELMD stock opened at $34.00 on Monday. The firm has a fifty day moving average price of $29.57 and a 200 day moving average price of $22.32. Electromed, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $34.25. The firm has a market cap of $287.57 million, a PE ratio of 47.22 and a beta of 0.31.

Electromed (NYSE:ELMD) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.13. The business had revenue of $14.67 million during the quarter. Electromed had a net margin of 11.34% and a return on equity of 15.32%.

Insiders Place Their Bets

In other Electromed news, Director Andrew Summers sold 12,731 shares of Electromed stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $29.98, for a total transaction of $381,675.38. Following the completion of the transaction, the director now directly owns 165,755 shares of the company’s stock, valued at $4,969,334.90. The trade was a 7.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.00% of the stock is currently owned by insiders.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.